Research progress on PD-1/PD-L1 inhibitors in prostate cancer immunotherapy / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 831-834, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-615649
ABSTRACT
The annual incidence of prostate cancer (PCa) continually increases. New PCa immune therapy has become the fourth line antitumor treatment following surgery, radiotherapy and chemotherapy. As the most promising research direction in cancer immunotherapy,immune checkpoint inhibitors, such as programmed cell death-1 and programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors, block PD-1 and its ligand PD-L1 and then terminate the negative control signal to the T cell, thereby facilitating T cell recovery and reversal of tumor immune-escaping mechanism. These processes restore the capability of T cells for immune response and inhibit and kill tumor cells. This review summarizes the progress on the current application of PD-1/PD-L1 inhibitors in PCa clinical trials.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS